Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest

Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut annualized relapse rates (ARR) ...